Drug name - Incivek

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7820671 VERTEX PHARMS Peptidomimetic protease inhibitors
Feb, 2025

(2 years from now)

CN1869061B VERTEX PHARMS Peptidomimetic Protease Inhibitors
Oct, 2016

(5 years ago)

CN101633636A VERTEX PHARMS Peptidomimetic Protease Inhibitors
Oct, 2016

(5 years ago)

CN1869061A VERTEX PHARMS Mimic Peptide Protease Inhibitor
Oct, 2016

(5 years ago)

CN101633636B VERTEX PHARMS Peptidomimetic Protease Inhibitors
Oct, 2016

(5 years ago)

CN1451014A VERTEX PHARMS Mimic Peptide Protease Inhibitor
Oct, 2016

(5 years ago)

CN100522991C VERTEX PHARMS Peptidomimetic Protease Inhibitors
Oct, 2016

(5 years ago)

CN101693672A VERTEX PHARMS Peptide-Mimetic Protease Inhibitors
Oct, 2017

(4 years ago)

CN101693672B VERTEX PHARMS Peptidomimetic Protease Inhibitors
Oct, 2017

(4 years ago)

IN212710B VERTEX PHARMS Peptidomimetic Compounds And Pharmaceutical Compositions
Aug, 2021

(1 year, 29 days ago)

IN200300242P2 VERTEX PHARMS Peptidomimetic Compounds And Pharmaceutical Compositions
Aug, 2021

(1 year, 29 days ago)

EP1878720B1 VERTEX PHARMS Process For Preparing Chiral Bicycloprolinates As Intermediates For The Preparation Of Peptidomimetic Protease Inhibitors
Aug, 2021

(1 year, 29 days ago)

EP2368877A1 VERTEX PHARMS Peptidomimetic Protease Inhibitors And Intermediates For Their Preparation As Treatment For Hcv Infection
Aug, 2021

(1 year, 29 days ago)

EP1958956A2 VERTEX PHARMS Peptidomimetic Protease Inhibitors
Aug, 2021

(1 year, 29 days ago)

EP1878720A1 VERTEX PHARMS Process For Preparing Chiral Bicycloprolinates As Intermediates For The Preparation Of Peptidomimetic Protease Inhibitors
Aug, 2021

(1 year, 29 days ago)

EP2368877B1 VERTEX PHARMS Peptidomimetic Protease Inhibitors And Intermediates For Their Preparation As Treatment For Hcv Infection
Aug, 2021

(1 year, 29 days ago)

EP1958956A3 VERTEX PHARMS Peptidomimetic Protease Inhibitors
Aug, 2021

(1 year, 29 days ago)

EP1958956B1 VERTEX PHARMS Peptidomimetic Protease Inhibitors
Aug, 2021

(1 year, 29 days ago)

EP1320540B9 VERTEX PHARMS Peptidomimetic Protease Inhibitors
Aug, 2026

(3 years from now)

EP1320540B1 VERTEX PHARMS Peptidomimetic Protease Inhibitors
Aug, 2026

(3 years from now)

EP1320540A2 VERTEX PHARMS Peptidomimetic Protease Inhibitors
Aug, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431615 VERTEX PHARMS Dose forms May, 2028

(5 years from now)

Drugs and Companies using TELAPREVIR ingredient

Treatment: Method of treating chronic hepatitis c

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
375MG TABLET;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.